Adaptive Biotechnologies Corp
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Adaptive Biotechnologies develops immune system-based diagnostics and therapeutics using its proprietary immunosequencing platform, which reads and translates the genetic sequences of T-cell and B-cell receptors. Its products include the MRD (measurable residual disease) test for blood cancers and T-Detect diagnostics that identify past infections based on immune response.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| LO FRANCISChief People Officer | Sell | $3.01M | 107,537at $28.02 | Sep 16, 2026 |
| LO FRANCISChief People Officer | Sell | $225K | 7,869at $28.57 | Sep 16, 2026 |
| OWEN KATEY EINTERZDirector | Sell | $250K | 9,615at $26.00 | Aug 26, 2026 |
| HERSHBERG ROBERTDirector | Sell | $382K | 15,664at $24.41 | Aug 18, 2026 |
| HERSHBERG ROBERTDirector | Sell | $366K | 15,000at $24.39 | Aug 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ADPT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.